Swiss National Bank Invests $467,000 in CeriBell, Inc. $CBLL

Key Points

• The Swiss National Bank acquired 24,300 shares of CeriBell, Inc. for approximately $467,000, representing about 0.07% ownership of the company as of its latest 13F filing.
• CeriBell's stock is currently valued at $11.60, with a market cap of $425.26 million and a negative PE ratio of -3.88.
• Eight analysts have given CeriBell a Buy rating with a consensus target price of $32.14, indicating their optimistic outlook on the stock's performance.

Swiss National Bank bought a new position in CeriBell, Inc. (NASDAQ:CBLL - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 24,300 shares of the company's stock, valued at approximately $467,000. Swiss National Bank owned approximately 0.07% of CeriBell as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. TPG GP A LLC purchased a new position in CeriBell in the fourth quarter worth $102,677,000. Red Tree Management LLC purchased a new stake in CeriBell during the fourth quarter valued at about $57,083,000. Yu Fan purchased a new stake in shares of CeriBell during the fourth quarter worth about $31,631,000. ABG WTT Global Life Science Capital Partners GP Ltd purchased a new stake in shares of CeriBell during the fourth quarter worth about $28,160,000. Finally, RA Capital Management L.P. purchased a new stake in shares of CeriBell during the fourth quarter worth about $21,340,000.

Wall Street Analyst Weigh In

Separately, BTIG Research started coverage on shares of CeriBell in a report on Tuesday, June 24th. They set a "buy" rating and a $30.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, CeriBell has an average rating of "Buy" and a consensus target price of $32.14.

Insider Buying and Selling

In other CeriBell news, Director Rebecca B. Robertson sold 11,188 shares of CeriBell stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $17.85, for a total value of $199,705.80. Following the completion of the sale, the director owned 10,042 shares of the company's stock, valued at approximately $179,249.70. The trade was a 52.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Xingjuan Chao sold 25,000 shares of the stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $17.70, for a total value of $442,500.00. Following the completion of the transaction, the chief executive officer directly owned 776,022 shares in the company, valued at approximately $13,735,589.40. This represents a 3.12% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,499 shares of company stock valued at $1,126,402. 20.10% of the stock is currently owned by insiders.

CeriBell Stock Down 3.5%

Shares of NASDAQ CBLL traded down $0.41 on Tuesday, reaching $11.42. 323,384 shares of the company's stock traded hands, compared to its average volume of 364,491. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75. The business's 50 day simple moving average is $14.67 and its two-hundred day simple moving average is $17.23. The company has a market cap of $418.66 million and a price-to-earnings ratio of -3.82. The company has a quick ratio of 12.91, a current ratio of 13.31 and a debt-to-equity ratio of 0.11.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.52 million. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.